Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1992-03-18
1993-07-27
Wityshyn, Michael G.
Drug, bio-affecting and body treating compositions
Lymphokine
424 854, 424 855, 424 856, 424 857, 424 88, 514 21, A61K 4500, A61K 3766, A61K 3702, A61K 3704
Patent
active
052308863
ABSTRACT:
A method for treating a cancer includes administration of an endotoxin to a patient at least a portion of whose neoplastic cells express the CD14 surface receptor. The endotoxin can be administered concurrently or sequentially with a binding protein capable of binding the endotoxin and, for example, where the endotoxin is a lipopolysaccharide or a nontoxic portion of a lipopolysaccharide, it may for example be administered concurrently with a lipopolysaccharide binding protein. Also, the method including a step of first determining whether a portion of the patient's neoplastic cells express the CD14 surface receptor and, if not, administering to the patient prior to or concurrently with the endotoxin a cytokine. Also, a composition for treating a cancer, that includes an endotoxin in combination with at least one cytokine. Administration of the composition can provide more effective treatment of cancers than administration of a composition containing one or more cytokines alone. The method of the invention, and administration of the composition according to the invention can induce autocrine and paracrine suppression of growth by leukemic cells, and thus can be particularly effective for treatment of acute myelogenous leukemia.
REFERENCES:
patent: 4851219 (1989-07-01), Sherwin
patent: 4863727 (1989-09-01), Zimmerman et al.
Spriggs, et al., "Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study", Sep. 7, 1988, J. Natl. Cancer Inst., vol. 80, pp. 1039-1044.
Creaven P., et al., "A Phase I Clinical Trial of Recombinant Human Tumor Necrosis Factor Given Daily for Five Days", 1989, Cancer Chemother. Pharmacol., vol. 23, pp. 186-191.
Lenk H., et al., "Phase II Clinical Trial of High-Dose Recombinant Human Tumor Necrosis Factor", 1989, Cancer Chemother. Pharmacol., vol. 24, pp. 391-392.
Demetri, G., et al., "A Phase I Trial of Recombinant Human Tumor Necrosis Factor and Interferon-Gamma: Effects of Combination Cytokine Administration In Vivo", Oct. 1989, Jour. Clin. Oncol., vol. 7, pp. 1545-1553.
Engelhardt, R., et al., "A Phase I Trial of Intravenously Administered Endotoxin", Mar. 1991, Proc. Am. Assoc. Cancer Res., vol. 32, p. 268, A1594.
Kunkel, S. L., et al., "Regulation of Macrophage Tumor Necrosis Factor Production by Prostaglandin E.sub.2 ", 1986, Bioc. Biop. Res. Comm., vol. 137, pp. 404-410.
Karck, U., et al., "The Release of Tumor Necrosis Factor From Endotoxin-Stimulated Rat Kupffer Cells is Regulated by Prostaglandin E.sub.2 and Dexamethasone", 1988, Jour. Hepat., vol. 7, pp. 352-361.
Levin S., et al., "Interferon System in Acute Viral Hepatitis", 1982, Lancet, vol. 1, pp. 592-594.
Treon, S. P., et al., "Demonstration of Concurrent Endotoxaemia and TNF-Aemia in Acute Viral Hepatitis Patients", 1991, Gastroenterology, vol. 100, p. A845.
Michie, H. R., et al., "Detection of Circulating Tumor Necrosis Factor After Endotoxin Administration", Jun. 9, 1988, New Eng. Jour. Med., vol. 318, pp. 1481-1486.
Pelner, L., et al., "Effects of Concurrent Infections and Their Toxins on the Course of Leukemia", 1958, Acta Med. Scand., vol. 338 (Suppl) pp. 1-47.
Barton, J. C., "Beneficial Effects of Hepatitis in Patients with Acute Myelogenous Leukemia", 1979, Ann. Int. Med. vol. 90, pp. 188-190.
Barton, J. C., et al., "Prognostic Significance of Hepatitis in Acute Myelogenous Leukemia", 1979, Clin. Res., vol. 27, p. 490A.
Foon, K. A., et al., "Posttransfusion Hepatitis in Acute Myelogenous Leukemia", Oct. 17, 1980, JAMA, vol. 244, pp. 1806-1807.
Rotoli, B., et al., "Long-Term Survival in Acute Myelogenous Leukemia Complicated by Chronic Active Hepatitis", 1982, New Eng. Jour. Med., vol. 307, pp. 1712-1713.
Helson, L., et al., "Effect of Tumour Necrosis Factor on Cultured Human Melanoma Cells", Dec. 1975, Nature, vol. 258, pp. 731-732.
Peetre, C., et al., "Effects of Recombinant Tumor Necrosis Factor on Proliferation and Differentiation of Leukemic and Normal Hemopoietic Cells In Vitro", 1986, Jour. Clin. Invest., vol. 78, pp. 1694-1700.
Munker R., et al., "In Vitro Action of Tumor Necrosis Factor on Myeloid Leukemia Cells", Apr. 1987, Blood, vol. 69, pp. 1102-1108.
Sugarman, B. J., et al., "Recombinant Human Tumor Necrosis Factor-.alpha.: Effects on Proliferation of Normal and Transformed Cells In Vitro", Nov. 1985, Science, vol. 230, pp. 943-945.
Craig, R. W., et al., "Differentiation-Inducing and Cytotoxic Effects of Tumor Necrosis Factor and Interferon-Gamma in Myeloblastic ML-1 Cells", 1989, Jour. Cel. Physiol. vol. 141, pp. 46-52.
Haranaka, K., et al., "Antitumor Activity of Murine Tumor Necrosis Factor (TNF) Against Transplanted Human Tumors in Nude Mice", May 27, 1984, Int. Jour. Cancer, vol. 34, pp. 263-267.
Rothstein, J. L., et al., "Synergy Between Tumor Necrosis Factor and Bacterial Products Causes Hemorrhagic Necrosis and Lethal Shock in Normal Mice", 1988, Proc. Natl. Acad. Sci., USA, vol. 85, pp. 607-611.
Mannel, D. N., et al., "Macrophages as a Source of Tumoricidal Activity (Tumor-Necrotizing Factor)", 1980, Infect. Immun., vol. 30, pp. 523-530.
Aggarwal, B. B., et al., "Human Tumor Necrosis Factor", 1985, Jour. Biol. Chem., vol. 260, pp. 2345-2354.
Mohri, M., et al., "Effects of Lipopolysaccharide on Phospholipase A, Activity and Tumor Necrosis Factor Expression in HL-60 Cells", 1990, Jour. Immunol., vol. 144, pp. 2678-2682.
Tobias, P. S., et al., "Identification of a Lipid A Binding Site in the Acute Phase Reactant Lipopolysaccharide Binding Protein", 1989, Jour. Biol. Chem., vol. 264, pp. 10867-10871.
Wright, S. D., et al., "CD14, a Receptor for Complexes of Lipopolysaccharide (LPS) and LPS Binding Protein", 1990, Science vol. 249, pp. 1431-1433.
Broitman Selwyn A.
Treon Steven P.
Koh Choon P.
Trustees of Boston University
Wityshyn Michael G.
LandOfFree
Tumor cell suppression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor cell suppression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor cell suppression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2340976